Vaginal concentrations of lactic acid potently inactivate HIV

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 9, 2013, Pages 2015-2025

  Aldunate, Muriel ^a,b   Tyssen, David ^a   Johnson, Adam ^a   Zakir, Tasnim ^a   Sonza, Secondo ^a,b   Moench, Thomas ^c   Cone, Richard ^d   Tachedjian, Gilda ^a,b  

^a BURNET INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c REPROTECT INC   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboxylic acids; Female reproductive tract; Vaginal lactobacilli; Virucidal

Indexed keywords

ACETIC ACID; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYDROCHLORIC ACID; LACTIC ACID;

ACIDITY; ARTICLE; BODILY SECRETIONS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; ISOMER; PH; VIRUS INACTIVATION;

CARBOXYLIC ACIDS; FEMALE REPRODUCTIVE TRACT; VAGINAL LACTOBACILLI; VIRUCIDAL;

BODY FLUIDS; FEMALE; HIV-1; HIV-2; HUMANS; LACTIC ACID; LACTOBACILLUS; MICROBIAL VIABILITY; TEMPERATURE; VAGINA; VIRUS INACTIVATION;

EID: 84881645337     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt156     Document Type: Article

References (74)

1. Hladik F, Hope TJ. HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 2009; 6: 20-8.
2. Saidi H, Jenabian MA, Belec L. Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides. AIDS Res Hum Retroviruses 2012; 28: 1485-97.
3. Boris S, Barbes C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect 2000; 2: 543-6.
4. Cone RA. Barrier properties of mucus. Adv Drug Deliv Rev 2009; 61: 75-85.
5. Lai SK, Wang YY, Hida K et al. Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci USA 2010; 107: 598-603.
6. Lai SK, Hida K, Shukair S et al. Human immunodeficiency virus type 1 is trapped by acidic but not by neutralized human cervicovaginal mucus. J Virol 2009; 83: 11196-200.
7. Mitchell C, Balkus JE, Fredricks D et al. Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA genital shedding in U.S. and Kenyan women. AIDS Res Hum Retroviruses 2013; 29: 13-9.
8. Sha BE, Zariffard MR, Wang QJ et al. Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005; 191: 25-32.
9. Baeten JM, Kahle E, Lingappa JR et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3: 77ra29.
10. Shukair SA, Allen SA, Cianci GC et al. Human cervicovaginal mucus contains an activity that hinders HIV-1 movement. Mucosal Immunol 2013; 6: 427-34.
11. Ravel J, Gajer P, Abdo Z et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4680-7.
12. Gajer P, Brotman RM, Bai G et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012; 4: 132ra52.
13. Allsworth JE, Lewis VA, Peipert JF. Viral sexually transmitted infections and bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Sex Transm Dis 2008; 35: 791-6.
14. Sewankambo N, Gray RH, Wawer MJ et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 1997; 350: 546-50.
15. Thoma ME, Gray RH, Kiwanuka N et al. The natural history of bacterial vaginosis diagnosed by gram stain among women in Rakai, Uganda. Sex Transm Dis 2011; 38: 1040-5.
16. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297-301.
17. Kaul R, Nagelkerke NJ, Kimani J et al. Prevalent herpes simplex virus type 2 infection is associated with altered vaginal flora and an increased susceptibility to multiple sexually transmitted infections. J Infect Dis 2007; 196: 1692-7.
18. Taha TE, Hoover DR, Dallabetta GA et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS 1998; 12: 1699-706.
19. Atashili J, Poole C, Ndumbe PM et al. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22: 1493-501.
20. Cohen CR, Lingappa JR, Baeten JM et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012; 9: e1001251.
21. Stamey TA, Timothy MM. Studies of introital colonization in women with recurrent urinary infections. I. The role of vaginal pH. J Urol 1975; 114: 261-3.
22. Hanna NF, Taylor-Robinson D, Kalodiki-Karamanoli M et al. The relation between vaginal pH and the microbiological status in vaginitis. Br J Obstet Gynaecol 1985; 92: 1267-71.
23. O'Hanlon DE, Moench TR, Cone RA. In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis 2011; 11: 200.
24. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 1999; 59: 91-5.
25. Fox CA, Meldrum SJ, Watson BW. Continuous measurement by radio-telemetry of vaginal pH during human coitus. J Reprod Fertil 1973; 33: 69-75.
26. Bai G, Gajer P, Nandy M et al. Comparison of storage conditions for human vaginal microbiome studies. PloS One 2012; 7: e36934.
27. Boskey ER, Cone RA, Whaley KJ et al. Origins of vaginal acidity: high D/L lactate ratio is consistent with bacteria being the primary source. Hum Reprod 2001; 16: 1809-13.
28. Boskey ER, Telsch KM, Whaley KJ et al. Acid production by vaginal flora in vitro is consistent with the rate and extent of vaginal acidification. Infect Immun 1999; 67: 5170-5.
29. Gregoire AT, Kandil O, Ledger WJ. The glycogen content of human vaginal epithelial tissue. Fertil Steril 1971; 22: 64-8.
30. Paavonen J. Physiology and ecology of the vagina. Scand J Infect Dis Suppl 1983; 40: 31-5.
31. Mirmonsef P, Gilbert D, Veazey RS et al. A comparison of lower genital tract glycogen and lactic acid levels in women and macaques: implications for HIV and SIV susceptibility. AIDS Res Hum Retroviruses 2012; 28: 76-81.
32. Meysick KC, Garber GE. Interactions between Trichomonas vaginalis and vaginal flora in a mouse model. J Parasitol 1992; 78: 157-60.
33. KlebanoffSJ, Coombs RW. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991; 174: 289-92.
34. O'Hanlon DE, Lanier BR, Moench TR et al. Cervicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli. BMC Infect Dis 2010; 10: 120.
35. Graver MA, Wade JJ. The role of acidification in the inhibition of Neisseria gonorrhoeae by vaginal lactobacilli during anaerobic growth. Ann Clin Microbiol Antimicrob 2011; 10: 8.
36. Ongradi J, Ceccherini-Nelli L, Pistello M et al. Acid sensitivity of cell-free and cell-associated HIV-1: clinical implications. AIDS Res Hum Retroviruses 1990; 6: 1433-6.
37. Kempf C, Jentsch P, Barre-Sinoussi FB et al. Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin. J Acquired Immune Defic Syndr 1991; 4: 828-30.
38. Martin LS, McDougal JS, Loskoski SL. Disinfection and inactivation of the human T lymphotropic virus type III/Lymphadenopathy-associated virus. J Infect Dis 1985; 152: 400-3.
39. O'Connor TJ, Kinchington D, Kangro HO et al. The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro. Int J STD AIDS 1995; 6: 267-72.
40. Connor RI. Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH. J Acquir Immune Defic Syndr 2006; 43: 499-501.
41. Salazar-Gonzalez JF, Salazar MG, Keele BF et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206: 1273-89.
42. Wei X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-905.
43. Tyssen D, Henderson SA, Johnson A et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PloS One 2010; 5: e12309.
44. Gorry PR, Bristol G, Zack JA et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol 2001; 75: 10073-89.
45. Keele BF, Giorgi EE, Salazar-Gonzalez JF et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105: 7552-7.
46. Wapling J, Moore KL, Sonza S et al. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol 2005; 79: 10247-57.
47. Yap SH, Sheen CW, Fahey J et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4: e335.
48. Price CF, Tyssen D, Sonza S et al. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PloS One 2011; 6: e24095.
49. Owen DH, Katz DF. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. J Androl 2005; 26: 459-69.
50. McWilliam Leitch EC, Stewart CS. Escherichia coli O157 and non-O157 isolates are more susceptible to L-lactate than to D-lactate. Appl Environ Microbiol 2002; 68: 4676-8.
51. Russell JB, Diez-Gonzalez F. The effects of fermentation acids on bacterial growth. Adv Microb Physiol 1998; 39: 205-34.
52. Alakomi HL, Skytta E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66: 2001-5.
53. Tang HM, Ou WB, Zhou HM. Effects of lactic acid and NaCl on creatine kinase from rabbit muscle. Biochem Cell Biology 2003; 81: 1-7.
54. Fichorova RN, Yamamoto HS, Delaney ML et al. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. mBio 2011; 2: e00168-11.
55. Mossop H, Linhares IM, Bongiovanni AM et al. Influence of lactic acid on endogenous and viral RNA-induced immune mediator production by vaginal epithelial cells. Obstet Gynecol 2011; 118: 840-6.
56. Witkin SS, Alvi S, Bongiovanni AM et al. Lactic acid stimulates interleukin-23 production by peripheral blood mononuclear cells exposed to bacterial lipopolysaccharide. FEMS Immunol Medical Microbiol 2011; 61: 153-8.
57. Boskey ER, Moench TR, Hees PS et al. A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm Dis 2003; 30: 107-9.
58. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62: 127-39.
59. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74: 6087-95.
60. Mirmonsef P, Zariffard MR, Gilbert D et al. Short-chain fatty acids induce pro-inflammatory cytokine production alone and in combination with toll-like receptor ligands. Am J Reprod Immunol 2012; 67: 391-400.
61. Senok AC, Verstraelen H, Temmerman M et al. Probiotics for the treatment of bacterial vaginosis. Cochrane Database Syst Rev 2009; Issue 4: CD006289.
62. Falagas ME, Betsi GI, Athanasiou S. Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect 2007; 13: 657-64.
63. Bradshaw CS, Pirotta M, De Guingand D et al. Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. PloS One 2012; 7: e34540.
64. Antonio MA, Meyn LA, Murray PJ et al. Vaginal colonization by probiotic Lactobacillus crispatus CTV-05 is decreased by sexual activity and endogenous lactobacilli. J Infect Dis 2009; 199: 1506-13.
65. Decena DC, Co JT, Manalastas RM Jr et al. Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. J Obstet Gynaecol Res 2006; 32: 243-51.
66. Andersch B, Forssman L, Lincoln K et al. Treatment of bacterial vaginosis with an acid cream: a comparison between the effect of lactate-gel and metronidazole. Gynecol Obstet Invest 1986; 21: 19-25.
67. Bahamondes MV, Portugal PM, Brolazo EM et al. Use of a lactic acid plus lactoserum intimate liquid soap for external hygiene in the prevention of bacterial vaginosis recurrence after metronidazole oral treatment. Rev Assoc Med Bras 2011; 57: 415-20.
68. Anderson DJ, Politch JA, Nadolski AM et al. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010; 24: 163-87.
69. Khanna KV, Whaley KJ, Zeitlin L et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002; 109: 205-11.
70. Salle B, Brochard P, Bourry O et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010; 202: 337-44.
71. Zhu T, Wang N, Carr A et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70: 3098-107.
72. Butler DM, DelportW, Kosakovsky Pond SL et al. The origins of sexually transmitted HIV among men who have sex with men. Sci Transl Med 2010; 2: 18re1.
73. Olmsted SS, Khanna KV, Ng EM et al. Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis 2005; 5: 79.
74. Abdool Karim SS, Richardson BA, Ramjee G et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011; 25: 957-66.